What does Preamble of Drug Deal Disclosure Act do?

This bill, formally titled 'To require the Department of Health and Human Services to release documents, communications, and other information relating to most favored nation pricing agreements and other private or confidential drug pricing deals struck with manufacturers, and for other purposes,' aims to compel the Department of Health and Human Services to disclose information. The bill specifically targets documents, communications, and other information related to 'most favored nation pricing agreements' and other private drug pricing deals with manufacturers.

What does SHORT TITLE. of Drug Deal Disclosure Act do?

This bill is formally titled the Drug Deal Disclosure Act.

What does RELEASE OF INFORMATION RELATING TO MOST-FAVORED-NATION PRICING of Drug Deal Disclosure Act do?

This section mandates the public release of records related to agreements between the Executive Office of the President, HHS, the Department of Commerce, or other federal entities and drug manufacturers. The release must occur within 30 days of the Act's enactment and be in a centralized, searchable, and downloadable format. Agreements covered include those entered into on or after January 20, 2025, that involve provisions related to reduced drug prices referencing foreign prices, direct-to-consumer sales, import exclusions, investment in the U.S., specialized treatment for demonstration projects, contributions to the Strategic National Stockpile, or priority review vouchers. Specific agreements publicly announced by the Executive Office of the President or manufacturers, such as those with AbbVie Inc., Amgen Inc., AstraZeneca plc., and others, are explicitly listed. Subsequent agreements meeting the specified criteria must also be disclosed within 30 days of ratification. Records may be withheld or redacted only for proprietary pricing information, legally prohibited disclosures, or information protected by other laws, with a written justification published and submitted to Congress. Withholdings are prohibited based on reputational harm or political sensitivity.

What does REPORT TO CONGRESS. of Drug Deal Disclosure Act do?

This section requires the Secretary to submit a report to specified congressional committees. The report must be submitted within 15 days of the completion of the release of agreements listed under section 2(a)(2). The report must list all documents and information released and withheld. The report must also include a summary of redactions and withholdings, along with the legal basis for those actions.

What does CONGRESSIONAL BUDGET OFFICE AND GOVERNMENT ACCOUNTABILITY of Drug Deal Disclosure Act do?

This section requires a joint report from the Director of the Congressional Budget Office and the Comptroller General of the United States. The report must be published within 90 days after the release of agreements listed under section 2(a)(2). The report will analyze the economic and budgetary effects of agreements disclosed under section 2. The analysis includes expected economic and budgetary consequences of each agreement. It will also detail direct cost savings for individuals in the United States, categorized by insurance status. The report will analyze the impact of the agreements on Medicare, Medicaid, and qualified health plans offered through the American Health Benefit Exchanges. The report will assess the impact on drug price competition, the Federal Anti-Kickback Statute, and health plan formulary design.

Back to bills

Drug Deal Disclosure Act

Last updated: 4/21/2026 · Introduced: 4/21/2026

Author: Ron Wyden (D-OR)

TL;DR (AI)

This bill mandates the public release of records related to drug pricing agreements between federal entities and manufacturers, including those referencing foreign prices or involving specific concessions, within 30 days of enactment.
The bill requires the Department of Health and Human Services to report to Congress on all released and withheld documents, detailing the legal justifications for any redactions or withholdings.
The Congressional Budget Office and Government Accountability Office must jointly analyze and report on the economic and budgetary effects of the disclosed agreements, including impacts on healthcare programs and drug price competition.

119th Congressin committeeOfficial page

Verified Votes

No verified votes yet.

Community Votes

No community votes yet. Be the first!

Voting as guest · Sign in for verified votes

Other Sections

Includes provisions on preamble, short title., and 3 more.

5 sections

Click "Show details" to explore individual sections. Use the community vote above or visit All Sections to vote per section.

Read official text

Want the full experience?

Create a free account to cast verified votes on each section, get a personalized summary, and track your voting history.

Create Free Account